MX2025006897A - Procedimientos para mejorar la farmacocinetica de migalastat - Google Patents

Procedimientos para mejorar la farmacocinetica de migalastat

Info

Publication number
MX2025006897A
MX2025006897A MX2025006897A MX2025006897A MX2025006897A MX 2025006897 A MX2025006897 A MX 2025006897A MX 2025006897 A MX2025006897 A MX 2025006897A MX 2025006897 A MX2025006897 A MX 2025006897A MX 2025006897 A MX2025006897 A MX 2025006897A
Authority
MX
Mexico
Prior art keywords
migalastat
pharmacokinetics
improving
methods
limiting
Prior art date
Application number
MX2025006897A
Other languages
English (en)
Spanish (es)
Inventor
Franklin Johnson
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2025006897A publication Critical patent/MX2025006897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2025006897A 2022-12-13 2025-06-12 Procedimientos para mejorar la farmacocinetica de migalastat MX2025006897A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263432235P 2022-12-13 2022-12-13
US18/315,928 US20240197706A1 (en) 2022-12-13 2023-05-11 Methods of improving the pharmacokinetics of migalastat
PCT/US2023/067656 WO2024129220A1 (en) 2022-12-13 2023-05-31 Methods of improving the pharmacokinetics of migalastat

Publications (1)

Publication Number Publication Date
MX2025006897A true MX2025006897A (es) 2025-07-01

Family

ID=86646511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025006897A MX2025006897A (es) 2022-12-13 2025-06-12 Procedimientos para mejorar la farmacocinetica de migalastat

Country Status (13)

Country Link
US (1) US20240197706A1 (enExample)
EP (1) EP4385509B1 (enExample)
JP (1) JP7757345B2 (enExample)
KR (1) KR20240094973A (enExample)
AU (1) AU2023396459A1 (enExample)
CA (1) CA3201512A1 (enExample)
CL (1) CL2025001743A1 (enExample)
CO (1) CO2025009079A2 (enExample)
DE (1) DE202023003007U1 (enExample)
IL (1) IL321404A (enExample)
MX (1) MX2025006897A (enExample)
TW (1) TW202423436A (enExample)
WO (1) WO2024129220A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
LT3470077T (lt) 2008-02-12 2021-02-25 Amicus Therapeutics, Inc. Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
CN103974619B (zh) * 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
JP2024542023A (ja) * 2021-11-03 2024-11-13 サンガモ セラピューティクス，インコーポレイテッド ファブリー病の治療のためのウイルスベクター構築物の使用方法

Also Published As

Publication number Publication date
JP2024084670A (ja) 2024-06-25
JP7757345B2 (ja) 2025-10-21
CA3201512A1 (en) 2024-06-13
CL2025001743A1 (es) 2025-10-03
KR20240094973A (ko) 2024-06-25
EP4385509B1 (en) 2025-09-03
IL321404A (en) 2025-08-01
DE202023003007U1 (de) 2025-07-21
WO2024129220A1 (en) 2024-06-20
TW202423436A (zh) 2024-06-16
EP4385509A1 (en) 2024-06-19
US20240197706A1 (en) 2024-06-20
AU2023396459A1 (en) 2025-06-26
CO2025009079A2 (es) 2025-09-29

Similar Documents

Publication Publication Date Title
MX2022003930A (es) Conjugados de péptido de camptotecina.
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2022002108A (es) Metodo para tratar canceres asociados con kras.
PH12022551424A1 (en) Kras g12c inhibitors.
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
PH12021553000A1 (en) Multispecific proteins
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2025001648A (es) Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras)
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
PH12022550015A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202103975B (en) Methods of treating disease with magl inhibitors
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2023012095A (es) Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
IL313734A (en) Gene therapy for lamin-A-related defects
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
WO2019143883A3 (en) Compositions and methods for the treatment of cancer
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1